OpenAI announced on October 20 that it has acquired Orchestra Bio, a four-year-old biotech software startup whose platform helps drugmakers coordinate the work of developing a medicine. Financial terms were not disclosed; Orchestra had raised roughly $20 million from backers including Andreessen Horowitz, Atria and 8VC.

Orchestra's AI agents handle the operational layer around the science: monitoring studies, tracking timelines and dependencies, and working out which activities are affected when something slips, such as a failed manufacturing batch delaying a clinical trial. Program leaders keep the decisions; the agents pull together the information and compare responses.

OpenAI is folding Orchestra's team and technology into Rosalind, its life-sciences AI platform, and the Rosalind Workbench tool for planning experiments and analyzing results. OpenAI says Rosalind already counts Moderna and Novo Nordisk as customers, and the deal is another example of the big labs building industry-specific software rather than only selling models.